Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution

Bone Marrow Transplantation volume 26, pages 845–849 (2000)Cite this article

Abstract

The purpose of this study was to analyze the outcome of patients with multiple myeloma (MM) responding to initial chemotherapy who received intensification with high-dose therapy/autotransplantation (HDT) as compared to that of those who were continued on standard chemotherapy. From 1 January 1990 to 30 June 1998, 64 patients with MM who were younger than 65 years achieved a response to initial chemotherapy. Due to referral reasons, patients preference or inclusion in trials, 31 patients received HDT as early intensification while 33 were continued on standard chemotherapy. The presenting features were similar in both groups, except for the median age, which was lower in the HDT group (53 vs 58 years, P = 0.007). Complete response – negative immunofixation – (CR) was achieved in 12 of 31 (39%) patients intensified with HDT and in two of 33 (6%) patients who were continued on conventional chemotherapy (P = 0.002). Event-free survival (EFS) was significantly longer in the HDT group (median, 43 vs 21 months; P = 0.007). Overall survival (OS) was not significantly different between groups (median, 62 vs 38 months; P = 0.21). However, patients in the HDT group who achieved CR had an EFS (median, 51 vs 31 months; P = 0.03) as well as an OS (median, not reached vs 50 months; P = 0.0006) significantly longer than those achieving a lower degree of response. In conclusion, this non-randomized study shows that early HDT increases CR rate and prolongs EFS. In addition, these results highlight CR as a crucial step for achieving long-lasting disease control and prolonged survival in patients with MM. Bone Marrow Transplantation (2000) 26, 845–849.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Bergsagel DE . Chemotherapy of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds) Myeloma. Biology and Management 2nd edn. Oxford University Press: Oxford 1998 pp 269–302

    Google Scholar 

  2. Gregory WM, Richards MA, Malpas JS . Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials J Clin Oncol 1992 10: 334–342

    Article  CAS  Google Scholar 

  3. Myeloma Trialists’ Collaborative Group . Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials J Clin Oncol 1998 16: 3822–3842

    Article  Google Scholar 

  4. Hjorth M, Holmberg E, Rödjer S et al. Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades Eur J Haematol 1999 62: 271–277

    Article  CAS  Google Scholar 

  5. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97

    Article  CAS  Google Scholar 

  6. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997 89: 789–793

    CAS  PubMed  Google Scholar 

  7. Palumbo A, Triolo S, Argentino C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients Blood 1999 94: 1248–1253

    CAS  PubMed  Google Scholar 

  8. Lenhoff S, Hjorth M, Holmberg et al. for the Nordic Myeloma Study Group (NMSG). Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed myeloma: a population-based study Blood 2000 95: 7–11

    CAS  PubMed  Google Scholar 

  9. Alexanian R, Weber D, Delasalle K et al. Impact of complete remission after ablative therapy for multiple myeloma Blood 1999 94: (Suppl. 1) 124a

    Google Scholar 

  10. Chronic Leukemia-Myeloma Task Force . National Cancer Institute. Proposed guidelines for protocol studies. II. Plasma cell myeloma Cancer Chemother Rep 1973 4: 145–158

    Google Scholar 

  11. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haematopoieic stem cell transplantation Br J Haematol 1998 102: 1115–1123

    Article  Google Scholar 

  12. Kaplan GL, Meier P . Non-parametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  13. Peto R, Pike MC . Conservation of the approximation Σ(O−E)2/E in the log-rank test for survival data or tumor incidence data Biometrics 1973 29: 759–784

    Google Scholar 

  14. Oken MM, Leong T, Kay NE et al. The effect of adding interferon (rIFN-alpha2) or high-dose cyclophosphamide to VBMCP to treat multiple myeloma: results from an ECOG phase III trial Blood 1995 86: (Suppl. 1) 441a

    Google Scholar 

  15. Bladé J, San Miguel JF, Fontanillas M et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients The Hematol J 2000 (in press

  16. Fermand JP, Ravaud P, Katsahian S et al. High dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients 55 to 65 years of age Blood 1999 94: (Suppl. 1) 396a

    Google Scholar 

  17. Hjorth M, Holmberg E, Rödjer S, Westin J for the Myeloma Group of Western Sweden . Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma Br J Haematol 1992 80: 55–61

    Article  CAS  Google Scholar 

  18. Bladé J, San Miguel JF, Fontanillas M et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated J Clin Oncol 1996 14: 2167–2173

    Article  Google Scholar 

  19. Webb IF, Anderson KC . Hematopoietic stem cell transplantation in multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds) Myeloma. Biology and Management 2nd edn. Oxford University Press: Oxford 1998 pp 311–331

    Google Scholar 

  20. Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma Blood 1994 84: 4278–4282

    CAS  PubMed  Google Scholar 

  21. Vesole D, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996 88: 838–847

    CAS  PubMed  Google Scholar 

  22. Barlogie B, Jagannath S, Nauche S et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma Bone Marrow Transplant 1998 21: 1101–1107

    Article  CAS  Google Scholar 

  23. Sirohi B, Powles R, Metha J et al. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system Br J Haematol 1999 107: 656–666

    Article  CAS  Google Scholar 

  24. Lahuerta JJ, Martínez-López K, de la Serna J et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients Br J Haematol 2000 109: 438–446

    Article  CAS  Google Scholar 

  25. Barlogie B, Desikan R, Munshi N et al. Durable CR in multiple myeloma (MM) in the absence of chromosome 13 deletion and with tandem melphalan-based high-dose therapy (HDT). The Arkansas experience with 1,000 consecutive patients Blood 1999 94: (Suppl. 1) 714a

    Google Scholar 

  26. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999 93: 55–65

    CAS  PubMed  Google Scholar 

  27. Lahuerta JJ, Martínez-López J, Grande C et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of the efficacy and toxicity from the Spanish Registry for transplantation in multiple myeloma Br J Haematol 2000 109: 138–147

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants from Fondo de Investigaciones Sanitarias de la Seguridad Social (FIS 96/0397, 00/0642), from Comissionat per a Universitats i Recerca de la Generalitat de Catalunya (SGR9800111) and José Carreras International Leukemia Foundation (FIJC-00/P-CR, FIJC-00/P-EM).

Author information

Authors and Affiliations

  1. Hematology Department, Institut of Hematology and Oncology, BMT Section, Postgraduate School of Haematology ‘Farreras Valentí’, Spain

    J Bladé, J Esteve, S Rives, C Martínez, M Rovira, A Urbano-Ispizua, E Carreras & E Montserrat

  2. Criotherapy Laboratory, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain

    P Marín

Authors
  1. J Bladé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Esteve
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Rives
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Urbano-Ispizua
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Marín
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E Carreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Montserrat
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bladé, J., Esteve, J., Rives, S. et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 26, 845–849 (2000). https://doi.org/10.1038/sj.bmt.1702622

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702622

Keywords

This article is cited by

Search

Advanced search

Quick links